Document is current

Article History

Received: 13 February 2025

Accepted: 19 March 2025

First Online: 7 May 2025

Declarations

:

: All authors have given lectures, received honoraria and research support and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies. However, no pharmaceutical company played any role in the scientific content of the present article, which has been written independently and reflects only the opinions of the authors, without no imput from the pharmaceutical industry. The following conflict of interests are reported. Špela Volčanšek has received lecture honoraria from Novo Nordisk, Eli Lilly, Medtronic, Abbott, AstraZeneca and Boehringer Ingelheim. Andrijana Koceva reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Medtronic and Pfizer. Mojca Jensterle has received lecture honoraria from Novo Nordisk, Eli Lilly, Pfizer, Amgen, Novartis and Sanofi, and is an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfizer. Andrej Janež has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Abbott, Novo Nordisk, Novartis and Swixx. Emir Muzurović has given lectures and participated in conferences and advisory boards sponsored by several pharmaceutical companies, including Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Medtronic and Servier.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.